Raphaël Ognar on Developing CIR-NK Cells to Better Target Cancer Cells

Video

The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.

“In early February, we had our proof-of-concept data in vitro with natural killer cells that are even better than our T-cell data. We saw, in vitro, that early-stage data are showing very specific targeting on leukemia cells expressing human leukocyte antigen-G (HLA-G), we have a couple of other specific points that will be highlighted in the presentation about how unique it is compared to an antibody and how differentiated it could be. More importantly, we recently just generated data that were done on a 1:10 effector to target ratio, with much fewer NK cells engineered within the environment oftumor cells and closer to what would be seen in real life.”

NKILT Therapeutics is focusing on improving targeting of cancer cells in leukemias and solid tumors by use of its novel Chimeric ILT-Receptor (CIR) platform, by which the company has developed CIR T-cells and, more, recently, CIR natural killer (CIR-NK) cells. While NKILT has not yet named its lead assets, it has revealed that its first target indication will be acute myeloid leukemia, followed by renal cell carcinoma, non-small cell lung cancer, colorectal cancer, and other HLA-G expressing cancers.

Raphaël Ognar, cofounder and chief executive officer of NKILT, presented positive preclinical data on CIR-NK cells at the World Oncology Cell Therapy Congress (WOCTC) held April 25-26 in Boston, Massachusetts. CGTLive spoke with Ognar to learn more about the potential advantages of the CIR platform in targeting cancer cells and the data presented. He noted that the company is targeting early 2024 to start interacting with the FDA.

Click here to read more coverage of WOCTC 2023.

REFERENCE
Targeting of HLA-G positive tumors with cytotoxic immune cells engineered with a chimeric ILT-Receptor. Presented at: WOCTC; April 25-26; Boston, Massachusetts.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.